Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01426217 · ClinicalTrials.gov registry record · NA
Reduction in IV Associated Contamination
A NA study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 594
- Enrollment target
NCT01426217: Completed NA study, sponsored by Dartmouth-Hitchcock Medical Center.
NCT01426217 is a NA study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 594 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01426217, a NA study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 594 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate whether implementing a novel syringe and IV stopcock cap system impregnated with alcohol will reduce IV catheter bacterial contamination and infections in patients.
Primary Outcome
The presence of bacteria in the stopcock lumen was assessed by analyzing swab cultures of the lumens. Each swab potentially containing bacteria from any of the 3 lumens of the stopcock sets were analyzed
Interventions
- DEVICE Passive Bundle PSI (Problem Solving Innovations) Medical HubScrub, PSI Medical DocIt
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 594 participants |
| Start Date | 2011-08 |
| Est. Completion | 2011-11 |
| Phase | NA |
What the finished NCT01426217 record still lists
NCT01426217 is an interventional study that assigns participants to a tested intervention. The registered 594 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 1 intervention - of which Passive Bundle PSI (Problem Solving Innovations) Medical HubScrub, PSI Medical DocIt is the first listed.
NCT01426217 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01426217 about?
NCT01426217 is a clinical study titled "Reduction in IV Associated Contamination". The purpose of this study is to investigate whether implementing a novel syringe and IV stopcock cap system impregnated with alcohol will reduce IV catheter bacterial contamination and infections in patients.
What is the current status of trial NCT01426217?
This trial is currently completed. It is a NA study. The enrollment target is 594 participants. The study started on 2011-08. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01426217?
The interventions under investigation include: Passive Bundle PSI (Problem Solving Innovations) Medical HubScrub, PSI Medical DocIt (DEVICE).
Who is sponsoring clinical trial NCT01426217?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01426217's enrollment target sits among peer trials
594 174th of 2000 higher than 1,826 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04701684 · 594 participants · NA
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
- NCT05491213 · 594 participants · NA
TELESCOPE- TELEhealth Shared Decision-making COaching
- NCT05867420 · 594 participants · Phase 1
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
- NCT06890884 · 594 participants · Phase 2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia